Who Paid My Doc
Stephen Crawford
Nuclear Cardiology Voorhees, NJ Doctor of Osteopathy
NPI 1447818679 CMS profile 6729786
2309 E Evesham Rd Ste 201A, Voorhees, NJ 08043
General payments
$1,112
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Stephen Crawford of Voorhees, NJ is reported in the CMS Open Payments database as having received $1,112 across 17 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 40th percentile of Nuclear Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $472 | 11 | |
| 2024 | General | $191 | 1 | |
| 2023 | General | $449 | 5 |
Beside peers
- Stephen Crawford
- Nuclear Cardiology median
- Middle half of Nuclear Cardiology
- National median
In program year 2025, general payments to Stephen Crawford were reported at $472. Among 99 Nuclear Cardiology profiles paid that year, the median was $434 and the middle half received between $138 and $985.
Show as a table
| Year | Stephen Crawford | Nuclear Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $552 | $91–$1,768 | $163 |
| 2020 | $0 | $204 | $61–$1,106 | $114 |
| 2021 | $0 | $354 | $99–$886 | $132 |
| 2022 | $0 | $506 | $101–$1,186 | $149 |
| 2023 | $449 | $545 | $148–$1,432 | $160 |
| 2024 | $191 | $484 | $131–$1,430 | $164 |
| 2025 | $472 | $434 | $138–$985 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 7 drugsPart D claims
114
Drug cost
$28,526
Branded share of claims
26.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 11 | $16,139 | |
| Jardiance Empagliflozin | Brand | 19 | $11,311 | |
| Rosuvastatin Calcium | Generic | 23 | $382 | |
| Losartan Potassium | Generic | 12 | $240 | |
| Metoprolol Succinate | Generic | 20 | $224 | |
| Atorvastatin Calcium | Generic | 13 | $147 | |
| Lisinopril | Generic | 16 | $83 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.
Records
17 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nuclear Cardiology in New Jersey
Brett Sealove
Nuclear Cardiology · Eatontown, NJ
Madhav Upadhyaya
Nuclear Cardiology · Tinton Falls, NJ
Mark Finch
Nuclear Cardiology · Cherry Hill, NJ
Hafeza Shaikh
Nuclear Cardiology · Willingboro, NJ
Nasser Chaudhry
Nuclear Cardiology · Cherry Hill, NJ
Ralph Russo
Nuclear Cardiology · Moorestown, NJ
Related records
Nuclear Cardiology in New Jersey
Practitioners in the same specialty and state, ranked by reported value.
All Nuclear Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in New Jersey
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.